Meropenem Steriscience

Meropenem, the active ingredient in Meropenem Steriscience, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, septicemia and meningitis in hospitalized patients. It is indicated for use in adult and pediatric patients when alternative therapies are unsuitable.

GNH USA supplies Meropenem Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality‑assured products that meet European regulatory standards.

Meropenem is a broad‑spectrum carbapenem antibiotic employed to manage serious bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: achieves bacterial eradication in severe abdominal sepsis and peritonitis. - Complicated urinary tract infections: clears resistant Gram‑negative pathogens causing pyelonephritis and cystitis. - Nosocomial pneumonia: treats hospital‑acquired and ventilator‑associated pneumonia caused by multidrug‑resistant organisms. - Septicemia: provides rapid bactericidal activity in bloodstream infections with high mortality risk. - Meningitis: penetrates the cerebrospinal fluid to eradicate pathogens responsible for bacterial meningitis.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Rash or pruritus - Headache - Injection site pain or phlebitis - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disorders - Clostridioides difficile‑associated colitis - Anaphylactic or severe hypersensitivity reactions - Neutropenia or agranulocytosis - Hepatic failure or severe transaminase elevation

Before initiating therapy, clinicians should consider several safety measures. - Renal function assessment: adjust dose in patients with impaired clearance. - Hepatic monitoring: observe liver enzymes during prolonged therapy. - CNS disorders: use caution in patients with seizure history. - Concomitant nephrotoxic drugs: avoid or monitor closely to reduce renal toxicity. - Known hypersensitivity: contraindicated in patients with allergy to carbapenems or beta‑lactams. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Valproic acid: carbapenems lower serum valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, enhancing toxicity. - Renal toxic agents (e.g., aminoglycosides, amphotericin B): combined use can exacerbate nephrotoxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance, requiring dose adjustment. - Anticoagulants (warfarin): monitor INR as meropenem may alter coagulation parameters.